Cardio Diagnostics Tests Covered by Atlas Healthcare

In a significant move for precision medicine, Cardio Diagnostics Holdings (NASDAQ: CDIO), an AI-powered precision cardiovascular medicine company, announced that Atlas Healthcare Physicians will provide coverage for its Epi+Gen CHD(TM) and PrecisionCHD(TM) tests. This independent physician association, serving managed care populations across Los Angeles and Orange counties, will cover these physician-ordered blood tests for eligible members with prior authorization. The tests are designed to assess coronary heart disease risk, support diagnosis, and enable personalized treatment planning. Epi+Gen CHD(TM) evaluates a patient's three-year risk of a coronary heart disease event, while PrecisionCHD(TM) helps diagnose coronary heart disease and identify its underlying molecular drivers. Both are noninvasive, blood-based diagnostics that do not require fasting or radiation exposure, making them ideal for broader adoption in community healthcare networks.

This coverage expansion is a key step in making precision cardiovascular medicine more accessible. Cardio Diagnostics leverages a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) to develop and commercialize its clinical tests. The company aims to become a leading medical technology firm focused on improving cardiovascular disease prevention, detection, and treatment. The news highlights the growing trend of integrating advanced diagnostics into managed care, potentially reducing the burden of heart disease through early and precise intervention.

For investors and the broader healthcare community, the latest news and updates relating to CDIO are available in the company’s newsroom at https://nnw.fm/CDIO. NetworkNewsWire, a specialized communications platform, distributed this announcement as part of its focus on financial news and content distribution. To view the full press release, visit https://nnw.fm/EFQen.